Aduro BioTech

Type: Company
Name: Aduro BioTech
First reported Jul 29 2014 - Updated Jul 30 2014 - 1 reports

Could a combination of two vaccines treat pancreatic cancer?

Researchers have developed a breakthrough therapy in the treatment of one of the world’s deadliest cancers: pancreatic cancer.Regulators designated Aduro Biotech Inc.'s new combination of CRS-207 and GVAX Pancreas drugs a "breakthrough therapy," putting ... [Published FOXNews.com - Jul 29 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

Clinical Development News, July 21-25

The following is a list of clinical development news from private and public companies during the week of July 21-25. Private companies: Aduro BioTech Inc., Berkeley, Calif., said that the combination of CRS-207 and GVAX Pancreas ... ... [Published Dow Jones Financial Information Services - Jul 25 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

New Cancer Treatment Receives "Breakthrough" Designation From FDA

A new treatment for one of the deadliest forms cancers has received a "breakthrough" designation from the Food and Drug Administration which means approval could come in months rather than years.Aduro BioTech, Inc. received the in the treatment of pancreatic ... [Published Clawson Patch - Jul 22 2014]
First reported Jul 21 2014 - Updated Jul 22 2014 - 9 reports

Vaccine Combo Gains ‘Breakthrough Therapy’ Status for Treatment of Pancreatic Cancer

Immunotherapy prolongs survival in mid-stage trialThe FDA has granted a “breakthrough therapy” designation for an investigational pancreatic cancer combination treatment consisting of GVAX Pancreas and CRS-207 immunotherapies (Aduro Biotech, Inc.).According ... [Published PT Community - Jul 22 2014]
First reported Jul 21 2014 - Updated Jul 21 2014 - 1 reports

Breakthrough Therapy Designation for Aduro's Immunooncology Combination for Pancreatic Cancer

Aduro BioTech joined the short list companies outside Big Pharma to pick up the FDA's coveted breakthrough therapy designation, impressing the agency with strong mid-stage results for its combo cancer therapy.An FDA breakthrough tag entitles Aduro to ... [Published American Journal of Managed Care - Jul 21 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 1 reports

Merck KGaA brings on U.S. Merck's Rossetti to head R

Merck KGaALuciano Rossetti  will head the R&D division.IlluminaTina Nova  joined as senior VP and general manager of oncology.Biotech>  Illumina ( $ILMN ) has named Tina Nova as its senior vice president and general manager of oncology.  Release>  ... [Published FierceBiotech - Jul 18 2014]
First reported Jul 17 2014 - Updated Jul 17 2014 - 8 reports

Aduro Biotech Names Industry Veteran And Academic Leader, To Its Board Of Directors

BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, Inc., a clinical-stage biotechnology company, today announced that renowned academic leader and industry veteran, Gerald Chan, DSc has joined its board of directors. Dr. Chan is the co-founder of Morningside, ... [Published BioSpace - Jul 17 2014]
First reported Jun 11 2014 - Updated Jun 12 2014 - 4 reports

Aduro BioTech secures $55 mln Series C

Clinical stage biotechnology company Aduro BioTech has closed a $55 million Series C financing. New investor Johnson & Johnson Development Corporation joined the Morningside group and other new and existing investors in the transaction. PRESS RELEASE ... [Published PE Hub Blog - Jun 12 2014]
First reported May 30 2014 - Updated May 31 2014 - 2 reports

Aduro inks agreement with Janssen Biotech for prostate cancer candidates

Aduro BioTech, a clinical-stage biotechnology company, has entered into an agreement granting Janssen Biotechan exclusive worldwide license to certain product candidates specifically engineered for the treatment of prostate cancer based on its novel. ... [Published BioPortfolio - May 31 2014]
First reported May 29 2014 - Updated May 30 2014 - 5 reports

Aduro licenses immunotherapy products to Janssen

Aduro BioTech Inc. (Berkeley, Calif.) granted the Janssen Biotech Inc. subsidiary of Johnson & Johnson (NYSE:JNJ) exclusive, worldwide rights to products based on Aduro's live-attenuated double-deleted Listeria monocytogenes (LADD) immunotherapy plat ... [Published BioPortfolio - May 30 2014]
First reported May 05 2014 - Updated May 05 2014 - 3 reports

Aduro BioTech Announces Initation of a Clinical Trial of Its Novel Immunotherapy in Patients with Brain Cancer at Providence Cancer Center

BERKELEY, Calif.--(EON: Enhanced Online News)--Aduro BioTech, Inc., a clinical stage biotechnology company, today announced that the first patients have been enrolled in a Phase 1 clinical trial to evaluate its novel immunotherapy ADU-623 in patients ... [Published EON Science - May 05 2014]
First reported Feb 10 2014 - Updated Feb 10 2014 - 12 reports

Aduro BioTech Announces Initiation of Phase 2b ECLIPSE Trial to Evaluate Treatment of Patients with Pancreatic Cancer with the Company’s Innovative Immunotherapies

BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, Inc. today announced the initiation of a Phase 2b clinical trial of the company’s immunotherapies GVAX Pancreas and CRS-207. The first patient has been treated in the randomized, controlled, multicenter ... [Published EON Transportation - Feb 10 2014]

Quotes

"We are encouraged by our Phase 2 results and look forward to completing enrolment in our Phase 2b ECLIPSE trial by end of 2015."
Original Article: NEXT ARTICLE More From BioPortfolio on "Aduro BioTech Receives FDA Breakthrough Therapy Designation for Innovative Pancreatic Cancer Combination Immunotherapy"
"It's a much more holistic way to address the disease - using the power of the body to fight the cancer instead of chemicals" he said
Original Article: NEXT ARTICLE More From BioPortfolio on "Aduro inks agreement with Janssen Biotech for prostate cancer candidates"

More Content

All (72) | News (29) | Reports (0) | Blogs (42) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Could a combination of two vaccines treat pancr... [Published FOXNews.com - Jul 29 2014]
Clinical Development News, July 21-25 [Published Dow Jones Financial Information Services - Jul 25 2014]
New Cancer Treatment Receives "Breakthrough" De... [Published Clawson Patch - Jul 22 2014]
Aduro’s pancreatic cancer immunotherapy gets FD... [Published Pharmaceutical Technology - Jul 22 2014]
Vaccine Combo Gains ‘Breakthrough Therapy’ Stat... [Published PT Community - Jul 22 2014]
Pancreatic cancer treatment that almost never w... [Published Business First of Buffalo - Jul 21 2014]
FDA’s Breakthrough Designation to Pancreatic Ca... [Published Oncology Times - Jul 21 2014]
Breakthrough Therapy Designation for Aduro's Im... [Published American Journal of Managed Care - Jul 21 2014]
Aduro BioTech Receives FDA Breakthrough Therapy... [Published BioPortfolio - Jul 21 2014]
Aduro BioTech Receives Breakthrough Therapy Des... [Published Mesothelioma News Today - Jul 21 2014]
Aduro pancreatic cancer treatment gets FDA brea... [Published Pharma Times - Jul 21 2014]
J&J partner Aduro grabs an FDA 'breakthrough' n... [Published FierceBiotech - Jul 21 2014]
ADURO BIOTECH RECEIVES BREAKTHROUGH THERAPY DES... [Published FierceBiotech - Jul 21 2014]
Aduro BioTech Receives Breakthrough Therapy Des... [Published CNBC - Jul 21 2014]
Aduro BioTech Receives Breakthrough Therapy Des... [Published Business Wire Health News - Jul 21 2014]
Merck KGaA brings on U.S. Merck's Rossetti to h... [Published FierceBiotech - Jul 18 2014]
Aduro Biotech Names Industry Veteran And Academ... [Published BioSpace - Jul 17 2014]
Aduro BioTech Names Industry Veteran and Academ... [Published Wall Street Business Network - Jul 17 2014]
Aduro BioTech Names Industry Veteran and Academ... [Published Enhanced Online News - Jul 17 2014]
Aduro BioTech Names Industry Veteran and Academ... [Published EON Business - Jul 17 2014]
Aduro BioTech Names Industry Veteran and Academ... [Published EON Science - Jul 17 2014]
Aduro BioTech Names Industry Veteran and Academ... [Published Business Wire Science: Science News - Jul 17 2014]
Aduro BioTech Names Industry Veteran and Academ... [Published Business Wire Professional Services News - Jul 17 2014]
Aduro BioTech Names Industry Veteran and Academ... [Published Business Wire Health News - Jul 17 2014]
Prostate Cancer - Pipeline Review, H1 2014 - Ne... [Published SBWire - Jul 14 2014]
Drugmakers taking a shot at cancer with vaccines [Published San Francisco Chronicle - Jul 01 2014]
J & J's alliance with life science companies fu... [Published Prlog - Jun 27 2014]
Aduro raises $55 million in series C financing [Published BioPortfolio - Jun 13 2014]
Aduro BioTech secures $55 mln Series C [Published PE Hub Blog - Jun 12 2014]
Aduro BioTech Secures $55 Million Series C Fina... [Published EON Science - Jun 11 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Aduro BioTech Receives Breakthrough Therapy Des... [Published Business Wire Health News - Jul 21 2014]
BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, Inc., a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for its pancreatic cancer combination treatment ...
Aduro BioTech Names Industry Veteran and Academ... [Published EON Business - Jul 17 2014]
BERKELEY, Calif.--(EON: Enhanced Online News)--Aduro BioTech, Inc., a clinical-stage biotechnology company, today announced that renowned academic leader and industry veteran, Gerald Chan, DSc has joined its board of directors. Dr. Chan is the co-founder ...
Aduro BioTech Names Industry Veteran and Academ... [Published EON Science - Jul 17 2014]
BERKELEY, Calif.--(EON: Enhanced Online News)--Aduro BioTech, Inc., a clinical-stage biotechnology company, today announced that renowned academic leader and industry veteran, Gerald Chan, DSc has joined its board of directors. Dr. Chan is the co-founder ...
Aduro BioTech Names Industry Veteran and Academ... [Published Business Wire Science: Science News - Jul 17 2014]
BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, Inc., a clinical-stage biotechnology company, today announced that renowned academic leader and industry veteran, Gerald Chan, DSc has joined its board of directors. Dr. Chan is the co-founder of Morningside, ...
Aduro BioTech Names Industry Veteran and Academ... [Published Business Wire Professional Services News - Jul 17 2014]
BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, Inc., a clinical-stage biotechnology company, today announced that renowned academic leader and industry veteran, Gerald Chan, DSc has joined its board of directors. Dr. Chan is the co-founder of Morningside, ...
1 2 3 4 5 6 7 8 9
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.